446 related articles for article (PubMed ID: 33431660)
21. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
[TBL] [Abstract][Full Text] [Related]
22. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
23. Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas.
Jain S; Van Scoyk A; Morgan EA; Matthews A; Stevenson K; Newton G; Powers F; Autio A; Louissaint A; Pontini G; Aster JC; Luscinskas FW; Weinstock DM
Blood; 2019 Oct; 134(17):1430-1440. PubMed ID: 31383641
[TBL] [Abstract][Full Text] [Related]
24. Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies.
Chan H; Trout CV; Mikolon D; Adams P; Guzman R; Mavrommatis K; Abbasian M; Hadjivassiliou H; Dearth L; Fox BA; Sivakumar P; Cho H; Hariharan K
Cancer Res Commun; 2024 Feb; 4(2):505-515. PubMed ID: 38319147
[TBL] [Abstract][Full Text] [Related]
25. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.
Gauttier V; Pengam S; Durand J; Biteau K; Mary C; Morello A; Néel M; Porto G; Teppaz G; Thepenier V; Danger R; Vince N; Wilhelm E; Girault I; Abes R; Ruiz C; Trilleaud C; Ralph K; Trombetta ES; Garcia A; Vignard V; Martinet B; Glémain A; Bruneau S; Haspot F; Dehmani S; Duplouye P; Miyasaka M; Labarrière N; Laplaud D; Le Bas-Bernardet S; Blanquart C; Catros V; Gouraud PA; Archambeaud I; Aublé H; Metairie S; Mosnier JF; Costantini D; Blancho G; Conchon S; Vanhove B; Poirier N
J Clin Invest; 2020 Nov; 130(11):6109-6123. PubMed ID: 33074246
[TBL] [Abstract][Full Text] [Related]
26. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
27. Targeting HDAC6 improves anti-CD47 immunotherapy.
Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
[TBL] [Abstract][Full Text] [Related]
28. Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels.
Tsai RK; Rodriguez PL; Discher DE
Blood Cells Mol Dis; 2010 Jun; 45(1):67-74. PubMed ID: 20299253
[TBL] [Abstract][Full Text] [Related]
29. Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates.
Sue M; Tsubaki T; Ishimoto Y; Hayashi S; Ishida S; Otsuka T; Isumi Y; Kawase Y; Yamaguchi J; Nakada T; Ishiguro J; Nakamura K; Kawaida R; Ohtsuka T; Wada T; Agatsuma T; Kawasaki N
PLoS One; 2024; 19(6):e0304985. PubMed ID: 38843278
[TBL] [Abstract][Full Text] [Related]
30. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
31. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
32. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages.
Ide K; Wang H; Tahara H; Liu J; Wang X; Asahara T; Sykes M; Yang YG; Ohdan H
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5062-6. PubMed ID: 17360380
[TBL] [Abstract][Full Text] [Related]
33. AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors.
Yang J; Deresa I; Ho WH; Long H; Maslyar D; Rosenthal A; Liang SC; Pincetic A
J Immunol; 2023 Jan; 210(2):204-215. PubMed ID: 36480261
[TBL] [Abstract][Full Text] [Related]
34. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
[TBL] [Abstract][Full Text] [Related]
35. The potentiating effect of hTFPI in the presence of hCD47 reduces the cytotoxicity of human macrophages.
Jung SH; Hwang JH; Kim SE; Young Kyu K; Park HC; Lee HT
Xenotransplantation; 2017 May; 24(3):. PubMed ID: 28393401
[TBL] [Abstract][Full Text] [Related]
36. Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.
Lv Z; Bian Z; Shi L; Niu S; Ha B; Tremblay A; Li L; Zhang X; Paluszynski J; Liu M; Zen K; Liu Y
J Immunol; 2015 Jul; 195(2):661-71. PubMed ID: 26085683
[TBL] [Abstract][Full Text] [Related]
37. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
[TBL] [Abstract][Full Text] [Related]
38. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Barclay AN; Van den Berg TK
Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
[TBL] [Abstract][Full Text] [Related]
39. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
[TBL] [Abstract][Full Text] [Related]
40. SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation.
Dehmani S; Nerrière-Daguin V; Néel M; Elain-Duret N; Heslan JM; Belarif L; Mary C; Thepenier V; Biteau K; Poirier N; Blancho G; Haspot F
Front Immunol; 2021; 12():732530. PubMed ID: 34925315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
